UPDATE: Sarepta Reports StrideBio Will Be Responsible For AAV Capsid Development, Non-Clinical Development, Manufacturing Of Preclinical Candidates To Be Selected For Advancement Into Clinical Studies

Benzinga · 11/14/2019 13:33